TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10537782
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with benzoporphyrin derivative
Study: 10537782
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with tin ethyl etiopurpurin
Study: 4044104
Drug: Caffeine trial
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine trial (5 mg caffeine/kg body weight)
Study: 27530657
Drug: Selenium 200
Normalized name: SELENIUM 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium 200 µg daily as selenized yeast
Study: 23963309
Drug: Low-dose drospirenone/estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose drospirenone/estradiol (0.25 mg/0.5 mg and 0.5 mg/0.5 mg)
Study: 23963309
Drug: Estradiol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (0.3 mg)
Study: 22882843
Drug: Rosuvastatin loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin loading before PCI (20 mg 12 hours before procedure, 10 mg 2 hours before procedure)
Study: 22882843
Drug: No rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rosuvastatin treatment before PCI (control group)
Study: 18216475
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream applied twice daily for 8 weeks
Study: 8556396
Drug: Early zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early zidovudine treatment (n = 170)
Study: 8556396
Drug: Later zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Later zidovudine treatment (n = 168)
Study: 24150216
Drug: F-SHAI (SHAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-SHAI (SHAI with fludarabine, 15 mg/m(2), 4 h before cytarabine)
Study: 24150216
Drug: SHAI (cytarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHAI (cytarabine, 1 g/m(2) bid, days 1‐2 and 8‐9; idarubicin 10 mg/m(2) daily, days 3‐4 and 10‐11)
Study: 8858272
Drug: Yohimbine (5.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (5.4 mg)
Study: 20837887
Drug: Pyridostigmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (60 mg)
Study: 20837887
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pyridostigmine and yohimbine
Study: 11562748
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with stem cell support
Study: 11856590
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy in inflammatory breast cancer
Study: 11856590
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy after conventional treatment
Study: 10205193
Drug: Atropine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (15 microg/kg bolus, 4 microg/kg/h infusion)
Study: 31831388
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy plus standard medical therapy
Study: 28017524
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg paricalcitol (PCT)/day for 12 weeks
Study: 28017524
Drug: PCT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT treatment
Study: 8241702
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (100 mg per day)
Study: 26780394
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mg lactose)
Study: 23171573
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g tannin-rich fiber (high-dose group, n = 13)
Study: 23171573
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g (placebo group, n = 14)
Study: 8968661
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days followed by 0.030 mg desogestrel for 7 days
Study: 1601378
Drug: Causal pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Causal pharmacological treatment of disordered spermatogenesis
Study: 28901214
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose infusion (TDI) of low molecular weight (LMW) iron dextran
Study: 28901214
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron ferrous fumarate 60 mg elemental iron three times daily
Study: 30660136
Drug: LSM &
Normalized name: I do not have enough information to determine the full generic name for the drug abbreviation "LSM &" based solely on the provided context. Drug abbreviations can vary and may not have a clear or standardized full generic name. Without more details about the specific drug or clinical trial, I cannot confidently provide the full generic name. The best I can suggest is to refer to the clinical trial documentation or consult a medical reference for more information about this particular drug abbreviation.
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSM & n‐3 (EPA + DHA concentrate 1.5 g/day, containing 0.6 g EPA + DHA)
Study: 22444781
Drug: Copper supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper supplementation (2 mg copper/day as copper glycinate) for 8 weeks
Study: 17571965
Drug: Very low-fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low-fat vegan diet supplemented with soy protein (58 g/day)
Study: 12224093
Drug: KTP (532
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTP (532 nm) laser treatment
Study: 10223495
Drug: Tolterodine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 0.5 mg twice daily
Study: 9426760
Drug: Tolterodine 1
Normalized name: tolterodine 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 1 mg twice daily
Study: 7799029
Drug: Glutathione (GSH)
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione (GSH) at a dose of 1.5 g/m2 in 100 mL of normal saline solution over a 15‐minute period immediately before CDDP administration, and at a dose of 600 mg by intramuscular injection on days 2 to 5.
Study: 7799029
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (placebo).
Study: 26834282
Drug: Pumpless group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumpless group (PL group: blood cardioplegia administration without roller pump)
Study: 26834282
Drug: Roller pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roller pump group (RP group: blood cardioplegia administration with roller pump)
Study: 19356420
Drug: Contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast agent use during dobutamine stress echocardiography (DSE)
Study: 11875694
Drug: Intratumoural/intrapleural SRL172
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoural/intrapleural SRL172 (1 microg to 1 mg) and intradermal SRL172 (1 mg) with standard chemotherapy (mitomycin‐C: 8 mg m(‐2), vinblastine: 6 mg m(‐2), cisplatin: 50 mg m(‐2))
Study: 11875694
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (mitomycin‐C, vinblastine, cisplatin)
Study: 11454528
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) - 5,000 IU intravenous bolus and continuous infusion of 18 IU/Kg/h (n=11)
Study: 29482720
Drug: Low-dose piperaquine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose piperaquine (LD-PIP)
Study: 28483414
Drug: P2-VP8-P[8] subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2-VP8-P[8] subunit rotavirus vaccine (30 μg)
Study: 28483414
Drug: P2-VP8-P[8] subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2-VP8-P[8] subunit rotavirus vaccine (60 μg)
Study: 28483414
Drug: P2-VP8-P[8] subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2-VP8-P[8] subunit rotavirus vaccine and Placebo
Study: 12627998
Drug: Pyridostigmine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (45 mg)
Study: 8059699
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg once daily
Study: 26358841
Drug: OKZ 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKZ 60 mg/120 mg/240 mg every four weeks (Q4W)
Study: 24751388
Drug: Intravenous nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalbuphine (10 μg/kg/hour)
Study: 24751388
Drug: Intravenous nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalbuphine (5 μg/kg/hour) and (10 μg/kg/hour)
Study: 29059694
Drug: Manual Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Medicine (MM)
Study: 15222407
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg)
Study: 11461714
Drug: Treatment procedure
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment procedure with accounted measurement error in log-transformed total rapid eye movement (REM) activity counts
Study: 9159697
Drug: Nortriptyline pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline pharmacotherapy
Study: 26644225
Drug: Fixed Dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose Combination (FDC) of ceftriaxone and sulbactam
Study: 26644225
Drug: FDC (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC (3 g/24 h)
Study: 1623444
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen injections
Study: 31541364
Drug: Osteopathic Manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manual Therapy (OMT)
Study: 12467746
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly oral prednisone (5mg/kg/dose)
Study: 779473
Drug: Parasympatholytic drug
Normalized name: Bos taurus parasympathetic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parasympatholytic drug therapy (propantheline bromide or dycyclomine HC1)
Study: 27670440
Drug: CoQ10 100
Normalized name: Walgreens CoQ10 100mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 100 mg daily
Study: 27670440
Drug: Control (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (current preventive drugs only)
Study: 19494028
Drug: CLA-mix (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA-mix (5.5 g/d of 40/40% of cis9,trans11-CLA and trans10,cis12-CLA)
Study: 16340945
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in biological CVD risk markers
Study: 17986538
Drug: Usual daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual daily exit-site care without mupirocin (Group C)
Study: 1399992
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine applied to the oral and nasal mucosa
Study: 6091169
Drug: Azathioprine and
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine and low-dose prednisolone
Study: 28166780
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (1.3 g/kg body weight) without resistance exercise
Study: 28166780
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (0.8 g/kg) with resistance exercise 3 times/week
Study: 28166780
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (0.8 g/kg) without resistance exercise
Study: 18059467
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid levels on day 7 of age during parenteral nutrition phase
Study: 16226864
Drug: Slow spinal
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow spinal injection (60 seconds) of 10 mg of hyperbaric bupivacaine 0.5% with 25 microg of fentanyl and 100 microg of morphine (group L)
Study: 14505907
Drug: 0.5mg dose
Normalized name: OZEMPIC 0.25mg or 0.5mg Dose 2mg/3mL Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg dose of L2-108/120 peptide
Study: 14505907
Drug: 0.1mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1mg dose of L2-108/120 peptide
Study: 11514043
Drug: Streptococcus pneumoniae
Normalized name: Streptococcus pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptococcus pneumoniae conjugate vaccine
Study: 29788347
Drug: Vaccine intervention
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine intervention
Study: 3492497
Drug: Urea administered
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea administered during cardiopulmonary bypass (CPB)
Study: 18258295
Drug: Resin cement
Normalized name: Quick Cure resin cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin cement (Rely‐X Arc, 3M) with metal tribochemically treated (Group G)
Study: 18258295
Drug: Resin cement
Normalized name: Quick Cure resin cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin cement (Compolute, 3M) with no surface treatment (Group B)
Study: 8173194
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) given by continuous infusion (96 h) iv and ip, modulated by high-dose folinic acid-iv
Study: 22911473
Drug: NPM1+/FLT3-ITD- subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPM1+/FLT3-ITD- subgroup (allo-HSCT, auto-HSCT, chemotherapy)
Study: 18991473
Drug: Cyclobenzaprine extended
Normalized name: cyclobenzaprine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine extended release (CER) 30 mg once daily
Study: 18991473
Drug: Cyclobenzaprine immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine immediate release (CIR) 10 mg three times daily
Study: 16274373
Drug: Acetaminophen (3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (3,000 mg/d)
Study: 11862365
Drug: High-dose ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ascorbic acid (3 x 1000 mg/day Cetebe)
Study: 2692022
Drug: Theophylline 390-900
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline 390-900 mg daily (1/3 in the morning, 2/3 in the evening)
Study: 2692022
Drug: Terbutaline 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 15 mg daily (7.5 mg in the morning and 7.5 mg in the evening)
Study: 11524396
Drug: Atrial therapies
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial therapies 'on' (pacing and shock therapies)
Study: 24736085
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 150 mg/day erlotinib (P/E)
Study: 24736085
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E) in patients aged 65 years or younger
Study: 1817934
Drug: AmF/SnF2 mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF/SnF2 mouth rinse solution, rinsed 1x/d for 16 months
Study: 7006182
Drug: Atenolol, 50
Normalized name: Atenolol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 50 mg, b.i.d.
Study: 7006182
Drug: Propranolol, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 80 mg, b.i.d.
Study: 31149004
Drug: Ketofol (ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketofol (ketamine 25 µg/kg/min + propofol 75 µg/kg/min)
Study: 29123173
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 IU bolus followed by 4,000 IU daily cholecalciferol)
Study: 22284287
Drug: Relaxin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxin (50 μg weekly injections for 8 weeks)
Study: 22284287
Drug: Placebo (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (weekly injections for 8 weeks)
Study: 17882138
Drug: Hydroxypropylmethylcellulose (HPMC)
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxypropylmethylcellulose (HPMC) at 15 g day(‐1) for 1 week (medium, high, ultra-high viscosity)
Study: 17882138
Drug: Hydroxypropylmethylcellulose (HPMC)
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxypropylmethylcellulose (HPMC) at 5 g day(‐1) for 8 weeks
Study: 17882138
Drug: Hydroxypropylmethylcellulose (HPMC)
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxypropylmethylcellulose (HPMC) at 15 g day(‐1) for 8 weeks
Study: 15144295
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg x kg(‐1) nefopam
Study: 11932287
Drug: Antiresorptive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive agents
Study: 9691099
Drug: Isotretinoin treatment
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin treatment (80 mg/d; 5 d)
Study: 9691099
Drug: LG1069 (RXR-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: LG1069 (RXR-specific agonist)
Study: 8583465
Drug: Intravenous captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous captopril 1.25 mg
Study: 2529815
Drug: Teicoplanin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (3 to 7 mg/kg every 12 h on the first day, followed by 3 to 7 mg/kg every 24 h; or 8 to 14.4 mg/kg per day for some cases)
Study: 2529815
Drug: Teicoplanin combined
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin combined with one or more antibiotics
Study: 360901
Drug: Ribavirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (300 mg/day, administered as capsules three times daily for 5 days)
Study: 30681017
Drug: SHP465 mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 mixed amphetamine salts (25/50 mg)
Study: 15122768
Drug: Infliximab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (10 mg/kg) with prednisolone (40 mg/day for 28 days)
Study: 15122768
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with prednisolone (40 mg/day for 28 days)
Study: 7625110
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of vaccine at STD clinic (centre A)
Study: 2122710
Drug: Intravenous taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous taurine (10 mg.kg‐1.d‐1)
Study: 211011
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of 500 μg of fenoterol
Study: 211011
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 200 μg of fenoterol
Study: 211011
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 400 μg of fenoterol
Study: 30636725
Drug: Combination EMG‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination EMG‐controlled electrical stimulation with visual EMG biofeedback group (CBG)
Study: 27268381
Drug: Carbetocin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100 μg IV)
Study: 26047975
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg TA-8995
Study: 26047975
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TA-8995 plus 20 mg atorvastatin
Study: 26047975
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg TA-8995
Study: 8355929
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg recombinant human relaxin in 3% methylcellulose gel
Study: 30971241
Drug: Late PMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late PMDI (periarticular multimodal drug injection) administered before prosthetic implantation
Study: 30971241
Drug: Early PMDI
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early PMDI (periarticular multimodal drug injection) administered just after knee arthrotomy
Study: 21896129
Drug: Ceramide-containing emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramide-containing emulsion cream
Study: 11269462
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (2 x 10(6) kallikrein inhibitor units)
Study: 11269462
Drug: Epsilon aminocaproic
Normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon aminocaproic acid (EACA) (20 g)
Study: 9505147
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for 12 weeks
Study: 9505147
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (diet and lifestyle advice and lovastatin 40 mg/dag during a 4-week run-in period)
Study: 9505147
Drug: Non-obese patients
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-obese patients receiving Metformin
Study: 2643167
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 to 20 mg once daily
Study: 125147
Drug: 6-Thioguanine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-Thioguanine (1.0 mg/kg/day orally)
Study: 125147
Drug: Procarbazine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procarbazine (3 mg/kg/day orally)
Study: 15920566
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml lignocaine 2% with sodium hyaluronidase 75 IU/ml (Group B)
Study: 9570604
Drug: Tetracaine 15
Normalized name: Chlorhexidine gluconate 500 microgram/mL and tetracaine 150 microgram/mL oromucosal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 15 mg